Business Description
Tarsus Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US87650L1035
Share Class Description:
TARS: Ordinary SharesDescription
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.48 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.29 | |||||
| Debt-to-EBITDA | -0.5 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 4.6 | |||||
| Beneish M-Score | 19.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1.1 | |||||
| 3-Year EPS without NRI Growth Rate | -2.4 | |||||
| 3-Year FCF Growth Rate | -6.4 | |||||
| 3-Year Book Growth Rate | -11 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 186.66 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.8 | |||||
| 9-Day RSI | 69.05 | |||||
| 14-Day RSI | 64.79 | |||||
| 6-1 Month Momentum % | -14.37 | |||||
| 12-1 Month Momentum % | 59.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.03 | |||||
| Quick Ratio | 6.99 | |||||
| Cash Ratio | 6.27 | |||||
| Days Inventory | 136.53 | |||||
| Days Sales Outstanding | 89.09 | |||||
| Days Payable | 963.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19 | |||||
| Shareholder Yield % | -9.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.5 | |||||
| Operating Margin % | -187.55 | |||||
| Net Margin % | -180 | |||||
| FCF Margin % | -155.3 | |||||
| ROE % | -69.1 | |||||
| ROA % | -51.79 | |||||
| ROIC % | -1591.79 | |||||
| 3-Year ROIIC % | -1478.8 | |||||
| ROC (Joel Greenblatt) % | -3964.08 | |||||
| ROCE % | -56.78 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.74 | |||||
| PB Ratio | 4.79 | |||||
| Price-to-Tangible-Book | 4.85 | |||||
| EV-to-EBIT | -6.59 | |||||
| EV-to-EBITDA | -6.64 | |||||
| EV-to-Revenue | 11.49 | |||||
| EV-to-Forward-Revenue | 3.71 | |||||
| EV-to-FCF | -7.4 | |||||
| Price-to-Net-Current-Asset-Value | 5.06 | |||||
| Price-to-Net-Cash | 6.06 | |||||
| Earnings Yield (Greenblatt) % | -15.17 | |||||
| FCF Yield % | -10.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TARS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tarsus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 83.374 | ||
| EPS (TTM) ($) | -4.48 | ||
| Beta | 0.93 | ||
| Volatility % | 69.39 | ||
| 14-Day RSI | 64.79 | ||
| 14-Day ATR ($) | 1.781141 | ||
| 20-Day SMA ($) | 27.87425 | ||
| 12-1 Month Momentum % | 59.53 | ||
| 52-Week Range ($) | 12.57 - 42.5 | ||
| Shares Outstanding (Mil) | 38.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tarsus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tarsus Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tarsus Pharmaceuticals Inc Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc(TARS)'s stock price today?
The current price of TARS is $31.69. The 52 week high of TARS is $42.50 and 52 week low is $12.57.
When is next earnings date of Tarsus Pharmaceuticals Inc(TARS)?
The next earnings date of Tarsus Pharmaceuticals Inc(TARS) is 2024-11-08 Est..
Does Tarsus Pharmaceuticals Inc(TARS) pay dividends? If so, how much?
Tarsus Pharmaceuticals Inc(TARS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers